Aparna Balasubramanian

Aparna Balasubramanian

Auto-generated profile, based on publicly available information

Aparna Balasubramanian

Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MMMeredith C. McCormack
Meredith C. McCormack
ABAparna Balasubramanian
Aparna Balasubramanian
EMElizabeth C. Matsui
Elizabeth C. Matsui
RPRoger D. Peng
Roger D. Peng
RWRobert A. Wise
Robert A. Wise
CKCorinne A. Keet
Corinne A. Keet

1 January 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
ERElizabeth A. Regan
Elizabeth A. Regan
MLMelissa E. Lowe
Melissa E. Lowe
BMBarry J. Make
Barry J. Make
JCJeffrey L. Curtis
Jeffrey L. Curtis
QCQuan (Grace) Chen
Quan (Grace) Chen
RWRobert A. Wise
Robert A. Wise
Rationale: The identification of early chronic obstructive pulmonary disease (COPD) is essential to appropriately counsel patients regarding smoking cessation, provide symptomatic treatment, and eventually develop disease-modifying treatments. Disease severity in COPD is defined using race-specific spirometry equations. These may disadvantage non-White individuals in diagnosis and care. Objectives: Determine the impact of race-specific equations on African American (AA) versus non-Hispanic White individuals. Methods: Cross-sectional analyses of the COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease) cohort were conducted, comparing non-Hispanic White (n = 6,766) and AA (n = 3,366) participants for COPD manifestations. Measurements and Main Results: Spirometric classifications using race-specific, multiethnic, and “race-reversed” prediction equations (NHANES [National Health and Nutrition Examination Survey] and Global Lung Function Initiative “Other” and “Global”) were compared, as were respiratory symptoms, 6-minute-walk distance, computed tomography imaging, respiratory exacerbations, and St. George’s Respiratory Questionnaire. Application of different prediction equations to the cohort resulted in different classifications by stage, with NHANES and Global Lung Function Initiative race-specific equations being minimally different, but race-reversed equations moving AA participants to more severe stages and especially between the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 0 and preserved ratio impaired spirometry groups. Classification using the established NHANES race-specific equations demonstrated that for each of GOLD stages 1–4, AA participants were younger, had fewer pack-years and more current smoking, but had more exacerbations, shorter 6-minute-walk distance, greater dyspnea, and worse BODE (body mass index, airway obstruction, dyspnea, and exercise capacity) scores and St. George’s Respiratory Questionnaire scores. Differences were greatest in GOLD stages 1 and 2. Race-reversed equations reclassified 774 AA participants (43%) from GOLD stage 0 to preserved ratio impaired spirometry. Conclusions: Race-specific equations underestimated disease severity among AA participants. These effects were particularly evident in early disease and may result in late detection of COPD.

14 March 2024 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
ABAparna Balasubramanian
Aparna Balasubramanian
RWRobert A. Wise
Robert A. Wise
SSSanja Stanojevic
Sanja Stanojevic
MMMartin R. Miller
Martin R. Miller
MMMeredith C. McCormack
Meredith C. McCormack
Background: Forced expiratory volume in 1 s quotient (FEV1Q) is a simple approach to spirometry interpretation that compares measured lung function to a lower boundary. This study evaluated how well FEV1Q predicts survival compared with current interpretation methods and whether race impacts FEV1Q.Methods: White and Black adults with complete spirometry and mortality data from the National Health and Nutrition Examination Survey (NHANES) III and the United Network for Organ Sharing (UNOS) database for lung transplant referrals were included. FEV1Q was calculated as FEV1divided by 0.4 L for females or 0.5 L for males. Cumulative distributions of FEV1were compared across races. Cox proportional hazards models tested mortality risk from FEV1Q adjusting for age, sex, height, smoking, income and among UNOS individuals, referral diagnosis. Harrell's C-statistics were compared between absolute FEV1, FEV1Q, FEV1/height2, FEV1z-scores and FEV1% predicted. Analyses were stratified by race.Results: Among 7182 individuals from NHANES III and 7149 from UNOS, 1907 (27%) and 991 (14%), respectively, were Black. The lower boundary FEV1values did not differ between Black and White individuals in either population (FEV1first percentile difference ≤0.01 L; p>0.05). Decreasing FEV1Q was associated with increasing hazard ratio (HR) for mortality (NHANES III HR 1.33 (95% CI 1.28–1.39) and UNOS HR 1.18 (95% CI 1.12–1.23)). The associations were not confounded nor modified by race. Discriminative power was highest for FEV1Q compared with alternative FEV1approaches in both Black and White individuals.Conclusions: FEV1Q is an intuitive and simple race-neutral approach to interpreting FEV1that predicts survival better than current alternative methods.


1 December 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
Enrico SchiaviEnrico Schiavi
Enrico Schiavi
MRMin Hyung Ryu
Min Hyung Ryu
LMLeonardo Martini
Leonardo Martini
ABAparna Balasubramanian
Aparna Balasubramanian
MMMeredith C. McCormack
Meredith C. McCormack
CHCraig P. Hersh
Craig P. Hersh
Rationale: For spirometry interpretation, the European Respiratory Society (ERS) and American Thoracic Society (ATS) recommend using z-scores, and the ATS has recommended using Global Lung Initiative (GLI) “Global” race-neutral reference equations. However, these recommendations have been variably implemented, and the impact has not been widely assessed in clinical or research settings. Objectives: To evaluate the ERS/ATS classification of airflow obstruction severity. Methods: In COPDGene (Genetic Epidemiology of COPD Study) (N = 10,108), airflow obstruction has been defined by an FEV1/FVC ratio <0.70, with spirometric severity graded from class 1 to class 4 based on race-specific percent predicted (pp) FEV1 cutoff points as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). We compared the GOLD approach, using National Health and Nutrition Examination Survey III race-specific equations, versus the application of GLI Global equations using the ERS/ATS definition of airflow obstruction as an FEV1/FVC ratio below the lower limit of normal and z-score–based FEV1 cutoff points of –1.645, –2.5, and –4 (“zGLI Global”). We tested the four-tier severity scheme for association with chronic obstructive pulmonary disease outcomes. Measurements and Main Results: The lowest agreement between ERS/ATS with zGLI Global and the GOLD classification was observed in individuals with milder disease (56.9% and 42.5% in GOLD stages 1 and 2, respectively), and race was a major determinant of redistribution. After adjustment for relevant covariates, zGLI Global distinguished all-cause mortality risk between normal spirometry and the first grade of chronic obstructive pulmonary disease (hazard ratio, 1.23; 95% confidence interval, 1.04–1.44; P = 0.014) and showed a linear increase in exacerbation rates with increasing disease severity in comparison with GOLD. Conclusions: The zGLI Global severity classification outperformed the GOLD criteria in the discrimination of survival, exacerbations, and imaging characteristics.

1 October 2025 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
AYAthiththan Yogeswaran
Athiththan Yogeswaran
PHPaul M. Hassoun
Paul M. Hassoun
KSKhaled Saleh
Khaled Saleh
MFMeike Fünderich
Meike Fünderich
ABAparna Balasubramanian
Aparna Balasubramanian
WSWerner Seeger
Werner Seeger
Rationale: Pulmonary hypertension (PH) in interstitial lung disease (ILD) lacks approved therapies. Objectives: The Pulmonary Vascular Research Institute GoDeep metaregistry collects real-world data of patients with PH from international PH referral centers. Methods: Patients with ILD-PH and relevant subgroups (idiopathic interstitial pneumonia [IIP], idiopathic pulmonary fibrosis [IPF]) were stratified by pulmonary vascular resistance (PVR). Kaplan-Meier survival analyses and adjusted Cox proportional hazards models were employed, additionally accounting for immortal time bias, sensitivity analyses, Heller explained relative risk statistics, and target trial emulation framework analysis. Measurements and Main Results: Among 34,482 patients, 940 with hemodynamically fully characterized incident ILD-PH (median age, 67 [IQR, 59–74] yr) were identified. A total of 62% had severe ILD-PH with PVR >5 Wood units (WU) and poor survival rates (29% and 18% at 3 and 5 yr), significantly worse than patients with ILD-PH with PVR ≤5 WU and patients with pulmonary arterial hypertension. Survival was poorest in severe IPF-PH. A total of 59% of all patients ILD-PH received PH-targeted therapy, predominantly phosphodiesterase-5 inhibitors (PDE5is). PDE5i treatment was consistently associated with significantly improved survival in patients with severe PH (hazard ratios of 0.537 [0.370–0.781], 0.461 [0.233–0.913], and 0.435 [0.215–0.8] for IIP-PH, IPF-PH, and IIP-PH with nintedanib/pirfenidone background therapy), but not in patients with less severe hemodynamic impairment, supported by sensitivity analyses, Heller statistics, and target trial emulation framework analysis. The survival statistics of patients with PDE5i-treated IIP-PH or IPF-PH were validated in the independent COMPERA registry. Combination therapy with PDE5is and inhaled prostacyclin analogues was superior to monotherapy using PDE5is (hazard ratio, 0.341; 0.205–0.566). Conclusions: Prognosis in ILD-PH was generally very poor and was related to PH severity. PDE5i treatment in severe IIP-PH and IPF-PH was associated with improved survival, which is to be further verified in controlled trials.